← Back to Search

Proteolytic Enzyme

Bromalian 50mg/kg/day for Cancer

Phase 2
Waitlist Available
Led By Benedict Liao, M.D.
Research Sponsored by Oeyama-Moto Cancer Research Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

The Phase II randomized, two-armed clinical study will investigate the efficacy of high dose versus low dose Bromelain (Comosain) in human subjects diagnosed with advanced late stage cancers. The study subjects will be randomly assigned to each group by a coin toss. Bromelain (Comosain) extract, derived from the stem and fruit of Ananas Comosus will be administered orally each day.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Using NCI standard measurement to measure primary target lesion size of various types of cancer pstients
Secondary outcome measures
Using NCI standard measurement to measure non-target lesion (tumor markers) value in various types of cancer patients
Other outcome measures
Using NCI standard to measure serious and non-serious outcomes in toxicity in various types of cancer patients

Trial Design

2Treatment groups
Active Control
Group I: Bromalian 50mg/kg/dayActive Control1 Intervention
The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
Group II: Bromalian 10 mg/kg/dayActive Control1 Intervention
The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.

Find a Location

Who is running the clinical trial?

Oeyama-Moto Cancer Research FoundationLead Sponsor
Benedict Liao, M.D.Principal InvestigatorOeyamaMoto Cancer research Foundation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
2014. "Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02340845.
All > Osa
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top